Compile Data Set for Download or QSAR
Report error Found 155 Enz. Inhib. hit(s) with all data for entry = 11560
TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626638(N-(6-(4-chloro-1H-1,2,3-triazol-1-yl)-2-fluoro-3-m...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626700(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626648(N-(1-amino-6,7-dihydro-5H-cyclopenta[c]pyridin-5-y...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626778(1-((6-cyclopropyl-8-(4-methylpiperazin-1-yl)imidaz...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626707(1-((6-cyclopropyl-8-(oxetan-3-ylethyl)imidazo[1,2-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626708(2-((6-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-2-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626710(1-((6-cyclopropyl-8-(4H-1,2,4-triazol-4-yl)imidazo...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626751(ethyl 2-((4-((4-carbamimidoyl-2,6-dimethylbenzyl)c...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626752(ethyl 3-(2-((4-((3-chloro-2-fluoro-6-(1H-tetrazol-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626754(4-((4-carbamimidoyl-2,6-dimethylbenzyl)amino)-6-((...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626748(3-(2-((4-((3-choro-2-fluoro-6-(1H-tetrazol-1-yl)be...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626750(2-((4-((4-carbamimidoyl-2,6-dimethylbenzyl)carbamo...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626755(N-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)benzyl)-1...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626691(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626757(N-(6-cyano-2-fluoro-3-methoxybenzyl)-1-((8-cyano-6...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626693(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626694(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626738(1-((6-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-2-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626667(2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626731(3-(6-cyclopropyl-2-((4-((2-fluoro-3-methoxy-6-(1H-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626732(1-((6-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626733(5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626668(US11787796, Compound I-29 | US11787796, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626719(US11787796, Compound I-80 | US11787796, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626746(3-(2-((4-((6-cyano-2-fluor-3-methoxybenzyl)carbamo...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626742(N-(4-carbamimidoyl-2,6-dimethylbenzyl)-1-((6-cyclo...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626654(N-(1-amino-3-methyl-6,7-dihydro-5H-cyclopenta[c]py...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626655(1-((8-((2-aminoethoxy)methyl)-6-cyclopropylimidazo...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626720(3-(6-cyclopropyl-2-((4-((2-fluoro-3-methoxy-6-(1H-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626715(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626664(1-((8-(aminomethyl)-6-cyclopropylimidazo[1,2-a]pyr...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626728(ethyl 3-(6-cyclopropyl-2-((4-((2-fluoro-3-methoxy-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626665(N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)-1-((6...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626729(N-(3-bromo-2-fluoro-6-(1H-tetrazol-1-yl)benzyl)-1-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626666(1-((6-cyclopropyl-8-(hydroxy(oxetan-3-yl)methyl)im...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626730(1-((6-cyclopropyl-8-(3-fluorooxetan-3-yl)imidazo[1...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626724(ethyl 3-(6-cyclopropyl-2-((4-((2-fluoro-3-methoxy-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626661(5-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)-N-(2-f...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626662(N-(1-amino-6,7-dihydro-5H-cyclopenta[c]pyridin-5-y...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626639(4-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)-N-(2-f...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626706(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626764(N-(5-chloro-2-(1H-tetrazol-1-yl)benzyl)-1-((6-cycl...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626701(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626646(1-((6-cyclopropyl-8-((2-(dimethylamino)ethoxy)meth...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626777(4-methoxypyridin-2-yl)methyl)-1H-1,2,3-triazole-4-...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626713(5-(2-((1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626714(Methyl 5-(2-((1-((6-cyclopropylimidazo[1,2-a]pyrid...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626641(7-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)-N-(2-f...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626687(1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM626747(ethyl 3-(2-((4-((6-cyano-2-fluoro-3-methoxybenzyl)...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

Displayed 1 to 50 (of 155 total ) | Next | Last >>
Jump to: